Phase 2 N=92 Randomized Double-blind Treatment

Study of the Medication Prazosin for Alcohol Dependence

Alcoholism

Bottom Line

View on ClinicalTrials.gov: NCT00762710 ↗

Enrolled (actual)

Serious AEs

5.4%

Results posted

Jun 2020

Primary outcome: Primary: Alcohol Consumption — 71.8; 66.5; 11.4; 22.6 percentage of days heavy drinking

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Prazosin medication (Drug); Placebo medication (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Seattle Institute for Biomedical and Clinical Research
Primary completion: Jun 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY Alcohol Consumption	71.8; 66.5; 11.4; 22.6	—

Summary

The purpose of this study is to determine whether the drug prazosin is effective for the treatment of alcohol dependency.

Eligibility Criteria

Inclusion Criteria

Current primary DSM-IV diagnosis of alcohol dependence(AD)
Heavy drinking in the last 30 days
At least 18 years of age
Good general medical health (see Exclusion Criteria below)
Capacity to provide informed consent
English fluency and literacy

Exclusion Criteria

Psychiatric/behavioral: current post-traumatic stress disorder(PTSD); psychiatric disorder requiring any medication other than anti-depressants; currently taking disulfiram, acamprosate, or naltrexone or planning to take any of these medications during the 12-week medication phase of the study; current dependence on any other psychoactive substance other than nicotine or cannabis; a current diagnosis of opioid abuse, use of any opioid- containing medications or benzodiazepines during the previous month, or UDA positive for opioids, benzodiazepines, or sedative hypnotics.
Medical: significant acute or chronic medical illness; women who are pregnant, nursing infant(s), or of childbearing potential and not using a contraceptive method judged by the study physician or PA to be effective; signs or symptoms of alcohol withdrawal at the time of initial consent
Legal involvement that could interfere with study treatment. Individuals court ordered for treatment will not be eligible to participate in this study.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00762710). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.